endpts.com·Jun 10, 2026
Ethyreal Bio has secured $101 million in funding to develop treatments for Graves' disease and thyroid eye disease, both of which are related autoimmune conditions. The company is backed by Atlas Venture and Medicxi.
Ethyreal Bio has secured $101M to address the autoimmune conditions Graves’ disease and thyroid eye disease, indicating a significant investment opportunity in the niche autoimmune treatment market. This funding, backed by Atlas Venture and Medicxi, highlights investor confidence and potential growth in targeting specific autoimmune diseases, making it a strategic area to watch for future developments in biotech investments.